Eli Lilly and Company (NYSE:LLY) CAO Donald A. Zakrowski Sells 1,000 Shares

Eli Lilly and Company (NYSE:LLY) CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock traded down $23.47 during mid-day trading on Thursday, hitting $798.39. 3,485,807 shares of the company were exchanged, compared to its average volume of 3,126,225. Eli Lilly and Company has a 12-month low of $711.40 and a 12-month high of $972.53. The company has a market capitalization of $757.01 billion, a P/E ratio of 68.18, a PEG ratio of 1.40 and a beta of 0.34. The business’s 50 day simple moving average is $829.78 and its two-hundred day simple moving average is $845.29. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its board has authorized a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on LLY shares. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research note on Friday, January 17th. Wolfe Research began coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Finally, Morgan Stanley set a $1,146.00 price target on Eli Lilly and Company in a report on Thursday, March 6th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $1,009.72.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. increased its stake in shares of Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Eli Lilly and Company during the third quarter worth approximately $606,000. Carrera Capital Advisors purchased a new position in Eli Lilly and Company during the third quarter worth approximately $244,000. Moser Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 40.0% in the 3rd quarter. Moser Wealth Advisors LLC now owns 455 shares of the company’s stock valued at $403,000 after purchasing an additional 130 shares during the last quarter. Finally, Empower Advisory Group LLC grew its stake in shares of Eli Lilly and Company by 4.3% during the 3rd quarter. Empower Advisory Group LLC now owns 139,274 shares of the company’s stock valued at $123,388,000 after buying an additional 5,682 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.